Evidence map›Paper›PMID 29062718›Full record

ArticleBBA clinical2017

Multiple

Simon P J Albracht, Johannes van Pelt

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BBA clinical, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. MultipleBBA clinical · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Simon P J AlbrachtRetired from the Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands.
Johannes van PeltNoordwest Ziekenhuisgroep, Laboratory of Clinical Chemistry, Hematology and Immunology, Alkmaar, The Netherlands.
Noordwest Ziekenhuisgroep · NLUniversity of Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the substrate DNP-α-GalNAc (2,4-dinitrophenyl-

Indexed as

A380, optical absorbance at 380 nmDMF, dimethylformamideDNP, 2,4-dinitrophenolDNP-α-GalNAcDNP-α-GalNAc, 2,4-dinitrophenyl-N-acetyl-α-d-galactosaminideGeneral tumour markerHuman serumMU, 4-methylumbelliferoneNaga6, the collective Naga-like activities in the pH 5 to 6 regionNaga8, the Naga-like activity in the pH 6.5 to 8 regionNaga, α-N-acetylgalactosaminidase (EC 3.2.1.49)pNP-α-GalNAc, para-nitrophenyl-α-GalNAcRT, room temperatureS.A., specific activity in nmol per min per mL serum (nmol min− 1 mL− 1), using 2 mM DNP-α-GalNAcTM, tumour markerα-GalNAc, N-acetyl-α-d-galactosaminideα-N-Acetylgalactosaminidase

Identifiers

PMID29062718
PMCPMC5647467
OpenAlexW2759778644

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.